BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10940652)

  • 1. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
    Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
    Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of a CD95 (Fas/Apo-1)-negative myeloma cell line.
    Kuribayashi N; Hata H; Yoshida M; Sonoki T; Nagasaki A; Kimura T; Harada N; Matsuzaki H
    Acta Haematol; 1999; 101(3):113-8. PubMed ID: 10352328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
    Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
    J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer.
    Szaflarski W; Sujka-Kordowska P; Pula B; Jaszczyńska-Nowinka K; Andrzejewska M; Zawierucha P; Dziegiel P; Nowicki M; Ivanov P; Zabel M
    Int J Oncol; 2013 Aug; 43(2):513-20. PubMed ID: 23739867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
    Chen GK; Durán GE; Mangili A; Beketic-Oreskovic L; Sikic BI
    Br J Cancer; 2000 Oct; 83(7):892-8. PubMed ID: 10970691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.
    Takara K; Obata Y; Yoshikawa E; Kitada N; Sakaeda T; Ohnishi N; Yokoyama T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):785-93. PubMed ID: 16534613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.
    Kuribayashi N; Hata H; Matsuzaki H; Yoshida M; Sonoki T; Nagasaki A; Kimura T; Harada N; Takatsuki K
    Med Oncol; 1998 Dec; 15(4):248-54. PubMed ID: 9951688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
    Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
    Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
    Hoffmann J; Schmidt-Peter P; Hänsch W; Naundorf H; Bunge A; Becker M; Fichtner I
    Clin Cancer Res; 1999 Aug; 5(8):2198-204. PubMed ID: 10473106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma.
    Xie J; Zhang L; Li M; Du J; Zhou L; Yang S; Zeng L; Li Z; Wang G; Wang D
    BMC Cancer; 2014 Jan; 14():11. PubMed ID: 24400589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells.
    Ishikawa T; Bao JJ; Yamane Y; Akimaru K; Frindrich K; Wright CD; Kuo MT
    J Biol Chem; 1996 Jun; 271(25):14981-8. PubMed ID: 8663001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane transport proteins associated with drug resistance expressed in human melanoma.
    Schadendorf D; Makki A; Stahr C; van Dyck A; Wanner R; Scheffer GL; Flens MJ; Scheper R; Henz BM
    Am J Pathol; 1995 Dec; 147(6):1545-52. PubMed ID: 7495278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
    Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
    Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient induction of the MRP/GS-X pump and gamma-glutamylcysteine synthetase by 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea in human glioma cells.
    Gomi A; Shinoda S; Masuzawa T; Ishikawa T; Kuo MT
    Cancer Res; 1997 Dec; 57(23):5292-9. PubMed ID: 9393752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels.
    Mulcahy RT; Bailey HH; Gipp JJ
    Cancer Chemother Pharmacol; 1994; 34(1):67-71. PubMed ID: 7513621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
    J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
    Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
    Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
    Diestra JE; Condom E; Del Muro XG; Scheffer GL; Pérez J; Zurita AJ; Muñoz-Seguí J; Vigués F; Scheper RJ; Capellá G; Germà-Lluch JR; Izquierdo MA
    J Urol; 2003 Oct; 170(4 Pt 1):1383-7. PubMed ID: 14501774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.